Slide 1: Q4 and Fiscal Year 2025 Year End Results Presentation
Q4 and Fiscal Year 2025 Year End Results Presentation July 29, 2025 | ir.ipatherapeutics.com | NASDAQ: IPA Presented by Dr. Jennifer Bath, CEO
Slide 2: Disclosures
Disclosures Disclaimer This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of Immuno Precise Antibodies Ltd. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the faciliti
Slide 3: Record earnings
Q4 and Fiscal Year 2025 Year End Earnings Call Corporate Update Record earnings Record quarterly revenue Expanded profit margins $7 Million Profit margin growth – 64% • Standout year with Q4 highest • Improvement reflects our operational quarterly revenue in company efficiency and disciplined execu
Slide 4: Operational efficiency and strong growth in Canada
Q4 and Fiscal Year 2025 Year End Earnings Call Corporate Update Operational efficiency Strong growth in Canada Record adjusted EBITDA $4.3 million in sales orders • Narrowed loss to $316,000 • Year-over-year sales in Canada increased by 47% • Underscores the strategy is working and moving us closer
Slide 5: Divestiture update and unified rebrand
Q4 and Fiscal Year 2025 Year End Earnings Call Corporate Update Divestiture initiative update Strategic development Final stages Unified rebrand – IPA EU Subsidiary next stage of growth • Capturing our evolution into a Bio-native AI company—integrating AI, data, and advanced lab research to transfo
Slide 6: Strategic collaborations: RIBOPRO and AI infrastructure with Vultr and AMD
Q4 and Fiscal Year 2025 Year End Earnings Call Corporate Update Q4 Strategic collaboration Technology strategic collaboration RIBOPRO Expanding AI infrastructure • Collaboration to integrate mRNA-based antigen expression with our in silico and with Vultr and AMD wet lab discovery capabilities • Upg
Slide 7: Undisclosed oncology partnership and FDA animal testing update
Q4 and Fiscal Year 2025 Year End Earnings Call Corporate Update Q4 Undisclosed partnership: oncology research FDA press release - regulatory requirement update USD $8-10 million April 2025 – shift toward • Antibody-drug conjugates (ADCs) and bispecifics antibodies for the treatment of cancer AI-bas
Slide 8: Expanded market presence and LENSai Epitope Mapping validation
Q4 and Fiscal Year 2025 Year End Earnings Call Corporate Update Q4 Expanded market presence LENSai Epitope Mapping validation Biologics discovery Head-to-head study confirms services introduction gold-standard performance in Cambridge, MA • Rivals existing methods in hours instead of weeks • Extend
Slide 9: Vaccine discovery and GLP-1 candidate
Q4 and Fiscal Year 2025 Year End Earnings Call Corporate Update Q4 Vaccine discovery GLP-1 Candidate Potential Universal AI designed GLP-1 peptides Dengue Vaccine independent study results • Highlights power of LENSai and opens door to • Matched or exceeded semaglutide in additional vaccines and th
Slide 10: LENSai immunogenicity validation and NASDAQ update
Q4 and Fiscal Year 2025 Year End Earnings Call Corporate Update Q4 LENSai Immunogenicity screening validation NASDAQ update Case study confirms Regained NASDAQ superior ADA risk prediction compliance • Composite score strongly correlates with • Satisfied $1.00 minimum bid requirement actual ADA inc
Slide 11: Leadership team additions
Q4 and Fiscal Year 2025 Year End Earnings Call Corporate Update Q4 Leadership team additions Board of Directors Advisory Board Jon Lieber Jeff Fried • Sr. Executive Officer, 30 years leadership • InterSystems, Director of Platform • Experience in biotechnology and life sciences, Strategy and Innova
Slide 12: Q4 and Fiscal Year 2025 Year End Financial Update
Q4 and Fiscal Year 2025 Year End Earnings Call Q4 and Fiscal Year 2025 Year End Financial Update ir.ipatherapeutics.com | NASDAQ:IPA ©2025 ImmunoPrecise Ant ibodi es LTD. All rights reserved. 12
Slide 13: Highest quarterly revenue to date
Q4 and Fiscal Year 2025 Year End Earnings Call Highest quarterly revenue to date $8.0 M $7.0 M $7.0 M $6.5 M $6.1 M $6.1 M $6.2 M $6.2 M $6.0 M $5.7 M $5.6 M $5.2 M $5.2 M $5.2 M $5.2 M $5.0 M $4.7 M $4.7 M $4.8 M $4.6 M $4.0 M $3.0 M $2.0 M $1.0 M $0.0 M Q1 Q2 Q3 Q4 FY22 FY23 FY24 FY25 Al l values
Slide 14: Fiscal year revenue
Q4 and Fiscal Year 2025 Year End Earnings Call Fiscal year revenue $30.0 M $24.5 M $24.5 M $25.0 M $20.7 M $20.0 M $19.3 M $15.0 M $10.0 M $5.0 M $0.0 M FY22 FY23 FY24 FY25 Al l values listed in CAD. ir.ipatherapeutics.com | NASDAQ:IPA ©2025 ImmunoPrecise Ant ibodi es LTD. All rights reserved. 14
Slide 15: Quarterly expenses
Q4 and Fiscal Year 2025 Year End Earnings Call Quarterly expenses Research & Development Sales & Marketing General & Administrative $1.5 M $1.3 M $1.2 M $5.0 M $1.0 M $4.1 M $1.1 M $1.0 M $0.9 M $3.7 M $4.0 M $1.0 M $0.8 M $3.0 M $0.6 M $2.0 M $0.5 M $0.4 M $0.2 M $1.0 M $0.0 M $0.0 M $0.0 M Q4 FY2
Slide 16: Improvement of adjusted EBITDA and increased cash
Q4 and Fiscal Year 2025 Year End Earnings Call Improvement of adjusted EBITDA and increased cash Adjusted EBITDA Q4 FY24 Q4 FY25 $0.0 M -$0.3 M -$0.5 M -$1.0 M -$1.5 M -$1.7 M -$2.0 M Cash on Hand April 30, 2025 $10.8 M April 30, 2024 $3.5 M Al l values listed in CAD. ir.ipatherapeutics.com | NASDA
Slide 17: Q&A
Q&A Q4 and FY 2025 Year End Earnings Call The HUB of July 29, 2025| ir.ipatherapeutics.com | NASDAQ: IPA Biotherapeutic ©2025 ImmunoPrecise Ant ibodi es LTD. All rights reserved. IPA is a t rademark of ImmunoPreci se Antibodies LTD. BioStrand is an independent ly operat ing subsidiary of ImmunoPreci